{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:19:34Z","timestamp":1778624374396,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210113"],"award-info":[{"award-number":["JP24fk0210113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00535-025-02282-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:55:59Z","timestamp":1751363759000},"page":"1272-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy"],"prefix":"10.1007","volume":"60","author":[{"given":"Takanori","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekatsu","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Mawatari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2282_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"2282_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u201393.","journal-title":"N Engl J Med"},{"key":"2282_CR3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20138.","journal-title":"Lancet Infect Dis"},{"key":"2282_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.35772\/ghm.2021.01083","volume":"3","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: from interferon to direct-acting antiviral. Glob Health Med. 2021;3:321\u201334.","journal-title":"Glob Health Med"},{"key":"2282_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/hepr.13810","volume":"52","author":"T Takehara","year":"2022","unstructured":"Takehara T, Izumi N, Mochida S, et al. Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan. Hepatol Res. 2022;52:833\u201340.","journal-title":"Hepatol Res"},{"key":"2282_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"2282_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/hepr.13739","volume":"52","author":"M Atsukawa","year":"2022","unstructured":"Atsukawa M, Tsubota A, Kondo C, et al. Time-course changes in liver functional reserve after successful sofosbuvir\/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022;52:235\u201346.","journal-title":"Hepatol Res"},{"key":"2282_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01963-2","author":"K Kotani","year":"2023","unstructured":"Kotani K, Enomoto M, Uchida-Kobayashi S, et al. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir\/velpatasvir for decompensated hepatitis C-related cirrhosis. J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s00535-023-01963-2.","journal-title":"J Gastroenterol"},{"key":"2282_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/hepr.13837","volume":"53","author":"T Sano","year":"2023","unstructured":"Sano T, Amano K, Ide T, et al. A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir\/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2023;53:26\u201334.","journal-title":"Hepatol Res"},{"key":"2282_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/hepr.13868","volume":"53","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Sakamori R, Maesaka K, et al. Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis. Hepatol Res. 2023;53:301\u201311.","journal-title":"Hepatol Res"},{"key":"2282_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/hepr.13926","volume":"53","author":"Y Uchida","year":"2023","unstructured":"Uchida Y, Imai Y, Tsuji S, et al. Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir. Hepatol Res. 2023;53:815\u201328.","journal-title":"Hepatol Res"},{"key":"2282_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","volume":"147","author":"F Marra","year":"2014","unstructured":"Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577-94.e1.","journal-title":"Gastroenterology"},{"key":"2282_CR13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1086\/646614","volume":"200","author":"M Zeremski","year":"2009","unstructured":"Zeremski M, Dimova R, Brown Q, et al. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis. 2009;200:1774\u201380.","journal-title":"J Infect Dis"},{"key":"2282_CR14","doi-asserted-by":"publisher","first-page":"14562","DOI":"10.1073\/pnas.1210592109","volume":"109","author":"P Farci","year":"2012","unstructured":"Farci P, Wollenberg K, Diaz G, et al. Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A. 2012;109:14562\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2282_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00535-014-1023-2","volume":"50","author":"Y Aoki","year":"2015","unstructured":"Aoki Y, Sugiyama M, Murata K, et al. Association of serum IFN-\u03bb3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol. 2015;50:894\u2013902.","journal-title":"J Gastroenterol"},{"key":"2282_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/apt.13389","volume":"42","author":"S Johansson","year":"2015","unstructured":"Johansson S, Talloen W, Tuefferd M, et al. Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients. Aliment Pharmacol Ther. 2015;42:1111\u201321.","journal-title":"Aliment Pharmacol Ther"},{"key":"2282_CR17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/hepr.13823","volume":"52","author":"T Suzuki","year":"2022","unstructured":"Suzuki T, Matsuura K, Nagura Y, et al. Serum angiopoietin-2 levels predict regression of Mac-2 binding protein glycosylation isomer-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatol Res. 2022;52:919\u201327.","journal-title":"Hepatol Res"},{"key":"2282_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/hepr.13962","volume":"54","author":"Y Nagura","year":"2024","unstructured":"Nagura Y, Suzuki T, Matsuura K, et al. Serum inducible protein 10 kDa\/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Hepatol Res. 2024;54:32\u201342.","journal-title":"Hepatol Res"},{"key":"2282_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/hepr.13861","volume":"53","author":"R Katoh","year":"2023","unstructured":"Katoh R, Maekawa S, Osawa L, et al. Significance of serum IP-10\/CXCL10 measurement in predicting post-direct acting antiviral treatment liver function in patients with HCV-decompensated liver cirrhosis. Hepatol Res. 2023;53:280\u20138.","journal-title":"Hepatol Res"},{"key":"2282_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13503","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020. https:\/\/doi.org\/10.1111\/hepr.13503.","journal-title":"Hepatol Res"},{"key":"2282_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"2282_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"2282_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292\u2013302.","journal-title":"Hepatology"},{"key":"2282_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"2282_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464\u201370.","journal-title":"Hepatology"},{"key":"2282_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00535-021-01845-5","volume":"57","author":"Y Tahata","year":"2022","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022;57:120\u201332.","journal-title":"J Gastroenterol"},{"key":"2282_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/hepr.13623","volume":"51","author":"K Maesaka","year":"2021","unstructured":"Maesaka K, Sakamori R, Yamada R, et al. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021;51:517\u201327.","journal-title":"Hepatol Res"},{"key":"2282_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2282_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-02039-x","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023. https:\/\/doi.org\/10.1007\/s00535-023-02039-x.","journal-title":"J Gastroenterol"},{"key":"2282_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14131","author":"Y Tahata","year":"2024","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy. Hepatol Res. 2024. https:\/\/doi.org\/10.1111\/hepr.14131.","journal-title":"Hepatol Res"},{"key":"2282_CR31","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1084\/jem.177.6.1809","volume":"177","author":"DD Taub","year":"1993","unstructured":"Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177:1809\u201314.","journal-title":"J Exp Med"},{"key":"2282_CR32","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.4049\/jimmunol.155.8.3877","volume":"155","author":"DD Taub","year":"1995","unstructured":"Taub DD, Sayers TJ, Carter CR, et al. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol. 1995;155:3877\u201388.","journal-title":"J Immunol"},{"key":"2282_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1359-6101(97)00015-4","volume":"8","author":"LF Neville","year":"1997","unstructured":"Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997;8:207\u201319.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2282_CR34","doi-asserted-by":"publisher","first-page":"18288","DOI":"10.1074\/jbc.273.29.18288","volume":"273","author":"Y Weng","year":"1998","unstructured":"Weng Y, Siciliano SJ, Waldburger KE, et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998;273:18288\u201391.","journal-title":"J Biol Chem"},{"key":"2282_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1189\/jlb.0303093","volume":"74","author":"CE Harvey","year":"2003","unstructured":"Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74:360\u20139.","journal-title":"J Leukoc Biol"},{"key":"2282_CR36","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.4049\/jimmunol.163.11.6236","volume":"163","author":"PL Shields","year":"1999","unstructured":"Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol. 1999;163:6236\u201343.","journal-title":"J Immunol"},{"key":"2282_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2008.10.020","volume":"136","author":"AP Holt","year":"2009","unstructured":"Holt AP, Haughton EL, Lalor PF, et al. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology. 2009;136:705\u201314.","journal-title":"Gastroenterology"},{"key":"2282_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/jmv.10431","volume":"70","author":"S Mihm","year":"2003","unstructured":"Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol. 2003;70:562\u201370.","journal-title":"J Med Virol"},{"key":"2282_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5009\/gnl.2011.5.4.506","volume":"5","author":"CR You","year":"2011","unstructured":"You CR, Park SH, Jeong SW, et al. Serum IP-10 levels correlate with the severity of liver histopathology in patients infected with genotype-1 HCV. Gut Liver. 2011;5:506\u201312.","journal-title":"Gut Liver"},{"key":"2282_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1078-0432.CCR-12-0928","volume":"19","author":"J Brownell","year":"2013","unstructured":"Brownell J, Polyak SJ. Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res. 2013;19:1347\u201352.","journal-title":"Clin Cancer Res"},{"key":"2282_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2022.102697","volume":"26","author":"GH Pereira","year":"2022","unstructured":"Pereira GH, Peixoto HR, Giusti ML, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Braz J Infect Dis. 2022;26: 102697.","journal-title":"Braz J Infect Dis"},{"key":"2282_CR42","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00535-023-02039-x","volume":"58","author":"Y Tahata","year":"2023","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023;58:1211\u201321.","journal-title":"J Gastroenterol"},{"key":"2282_CR43","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","volume":"214","author":"J Hengst","year":"2016","unstructured":"Hengst J, Falk CS, Schlaphoff V, et al. Direct-acting antiviral-induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis. 2016;214:1965\u201374.","journal-title":"J Infect Dis"},{"key":"2282_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/infdis\/jiv391","volume":"213","author":"M Spaan","year":"2016","unstructured":"Spaan M, van Oord G, Kreefft K, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis. 2016;213:216\u201323.","journal-title":"J Infect Dis"},{"key":"2282_CR45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jhep.2021.07.003","volume":"75","author":"C Montaldo","year":"2021","unstructured":"Montaldo C, Terri M, Riccioni V, et al. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. J Hepatol. 2021;75:1301\u201311.","journal-title":"J Hepatol"},{"key":"2282_CR46","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/liv.14186","volume":"40","author":"F Tacke","year":"2020","unstructured":"Tacke F, Boeker KHW, Klinker H, et al. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int. 2020;40:539\u201348.","journal-title":"Liver Int"},{"key":"2282_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/hep.31700","volume":"74","author":"F Wellh\u00f6ner","year":"2021","unstructured":"Wellh\u00f6ner F, D\u00f6scher N, Woelfl F, et al. Eradication of chronic HCV infection: improvement of dysbiosis only in patients without liver cirrhosis. Hepatology. 2021;74:72\u201382.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-025-02282-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-025-02282-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T08:02:56Z","timestamp":1758441776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-025-02282-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1007\/s00535-025-02282-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Satoshi Mochida received research grants from Janssen Pharmaceutical K. K., EA Pharma Co, Ltd., MIC Medical Corp., AbbVie GK, EPS International Holdings Co., Ltd. and Gilead Sciences, Inc. and scholarship grants from Toray Industries Inc, AbbVie GK, ASKA Pharmaceutical Co., Ltd, Eisai Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd and EA Pharma Co., Ltd. and is on the speakers\u2019 bureau for MSD K. K, Gilead Sciences, Inc, Toray Industries Inc, AbbVie GK, Sumitomo Dainippon Pharma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd and ASKA Pharmaceutical., Ltd. Norifumi Kawada received research grants from Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd, AstraZeneca plc, MSD co., Ltd, Gilead Sciences, Inc, GlaxoSmithKline plc and Bristol Myers Squibb. and scholarship grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Eisai Co., Ltd. and is on the speakers\u2019 bureau for AbbVie GK, MSD Co., Ltd and Gilead Sciences, Inc. Masayuki Kurosaki is on the speakers\u2019 bureau for Gilead Sciences, Inc and AbbVie GK. Hitoshi Yoshiji received research grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Asuka Pharmaceutical Co., Ltd. and is on the speakers\u2019 bureau for Gilead Sciences, Inc, Otsuka Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Asuka Pharmaceutical Co., Ltd and AbbVie GK. Taro Takami is on the speakers\u2019 bureau for Gilead Sciences, Inc., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Yasuhiro Asahina belongs to a donation-funded department funded by Gilead Sciences, Inc., AbbVie GK, Toray Industries Inc and Fujirebio Inc. Tetsuo Takehara received research grants from Gilead Sciences, Inc., MSD, AbbVie GK. and Chugai Pharmaceutical Co., Ltd. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., AbbVie GK and MSD. Takahiro Kodama is on the speakers\u2019 bureau for Gilead Sciences, Inc., and AbbVie GK. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board at Osaka University Hospitals (18431 and 22285) and all other institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Basically, informed consent was obtained from study patients. Registry and the Registration No. of the study\/trial: This study was registered to the University Hospital Medical Information Network (36150).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}